prostate%20cancer
PROSTATE CANCER

Prostate cancer is the cancer that occurs in the male's prostate.

It is the most common cancer in men >50 years of age.

Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.

Surgical Intervention

Radical Prostatectomy

  • Removal of the prostate gland as a whole, including the seminal vesicles, ampulla of the vas deferens, and lymph nodes with preservation of function (continence, potency)
  • First-line treatment for patients with tumors confined to the prostate gland, with low-intermediate risk disease, and life expectancy of ≥10 years
    • Treatment option for patients with high- to very high-risk disease and a salvage therapy option for patients with biochemical recurrence after external beam radiation therapy (EBRT), brachytherapy or cryotherapy if with no metastases, ISUP grade 4-5 or PSA >20 ng/mL
  • High cure rate for patients with purely localized disease

Pelvic Lymph Node Dissection (PLND)

  • Recommended for patients with high-risk or locally advanced disease with nodal metastases, done concurrently with radical prostatectomy
  • Extended pelvic lymph node dissection, which involves the removal of the lymph nodes in the area of the external iliac artery and vein, veins within the obturator fossa, and medial and lateral nodes of the internal iliac artery, is preferred due to its completeness of disease staging and is therapeutically more advantageous in patients with microscopic metastases compared to PLND alone
    • May be done in patients with intermediate risk with >5% estimated risk of lymph node involvement

Orchiectomy

  • Also called surgical castration, total or subcapsular pulpectomy, where one or both testicles (bilateral orchiectomy) are removed
  • Recommended castration method for patients with intermediate- to very high-risk prostate cancer and those with treatment-naive locally advanced and metastatic prostate cancer

Cryosurgery (Cryotherapy/Cryoablation)

  • Minimally invasive surgical procedure that involves freezing and destruction of tumor tissues
  • Treatment option for patients with high-risk prostate cancer following radiation therapy and as initial treatment for patients with low- to intermediate-risk localized or locally advanced stages
    • High-risk prostate cancer following radiation therapy
    • Low- to intermediate-risk prostate cancer not a candidate for prostatectomy due to comorbidities
    • Relative contraindications to radiotherapy
  • Prostate volume should be <40 mL at the time of therapy
  • Lower risk of damage to nearby structures and complication secondary to radical treatment
  • Studies reported a range of 52%-92% biochemical disease-free survival within 5-7 years, depending on criteria used
    • Discussion with patient should be made regarding the lack of long-term efficacy comparative outcome data

Other Ablative Techniques

  • Eg high-intensity focused ultrasound (HIFU), radiofrequency ablation and electroporation
  • HIFU is a minimally invasive procedure that uses focused ultrasound waves emitted from a transducer to cause thermal damage to malignant tissues
    • Alternative treatment to localized prostate cancer with disease recurrence after radiotherapy 
    • May be applicable for low- to intermediate-risk patients but further studies are needed to conclude use
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).